Panaxium is proud to be recently selected as a research partner investigating bioelectronics for treating glioblastoma tumours
The project “Flexible Implantable Organic Electronic Devices For Pulsed Electric Treatment Of Glioblastoma”or FIDELGLIO, was recently announced by the ANR (Agence nationale de la recherche) in France. Led by Prof. Rodney O’Connor, PhD., Head of the Department of Bioelectronics at the Campus Georges Charpak of the l’École des mines de Saint-Étienne, in Gardanne, France. Dr. O’Connor is a world-leader in the science of influencing cancerous neural cells with electric fields. As described on the ANR website, “FIDELGLIO will develop and test a flexible implantable organic electronic device for the treatment of glioblastoma (GBM) with pulsed electric fields. Along with Prof. O’Connor’s team at EMSE-CMP, and Panaxium as an industry partner, the project includes partners at Institut de Neurosciences de la Timone, located in Marseille. The project began in January, and will continue for three years, with the stated “potential to deliver a novel, safe treatment for GBM that can rapidly reach the medical market for humans.” Panaxium is excited to be able to contribute to his project by lending the company’s leading expertise in developing micro-scale organic bioelectronic devices.